Shots:

• F-star is eligible to receive up front and near-term payments of ~$12M & will be eligible for ~$300M as development & sales milestone along with royalties. Payments received by F-star are subject to a CVR agreement in which a portion will be payable to F-star’s investors that were previously stockholders of Spring Bank
• AstraZeneca will obtain the global rights to research- develop & commercialize next-generation STING inhibitor compounds & get exclusive access to F-star’s novel preclinical STING inhibitors
• Additionally- F-star will retain rights to all STING agonists- currently in clinical development for patients with cancer

  Ref: GlobeNewswire | Image: AstraZeneca